Literature DB >> 1291569

Propofol anaesthesia for ultrasound guided oocyte retrieval: accumulation of the anaesthetic agent in follicular fluid.

T Coetsier1, M Dhont, P De Sutter, E Merchiers, L Versichelen, M T Rosseel.   

Abstract

Propofol (2,6-diisopropylphenol, Diprivan, ICI-Pharmaceuticals, Manchester, UK) is widely used either as an adjunct in general anaesthesia or as sole anaesthetic agent by the continuous intravenous route and intermittent bolus injections for minor surgical interventions. For several years, we have been using this kind of anaesthesia in transvaginal oocyte retrieval for in-vitro fertilization (IVF), allowing a completely painless puncture on an out-patient basis. From in-vitro studies on mouse oocytes, it appeared that propofol could be deleterious for fertilization in a dose- and time-dependent manner. We therefore investigated the concentrations of propofol in follicular fluid during oocyte retrieval in women. We measured propofol levels in serum and follicular fluid of nine patients at fixed intervals during ultrasound guided oocyte retrieval. Serum levels fluctuated randomly, due to interference from top-off doses of propofol. In follicular fluid, however, we found a steady increase of propofol levels, which was proportional to the total dose of propofol administered. These data indicate that propofol accumulates in follicular fluid. Although it seems unlikely that propofol as used in the present protocol exerts a clinically significant unfavourable effect on IVF, we suggest that the oocyte retrieval procedure should be kept as short as possible, in order to limit the accumulation of the anaesthetic in follicular fluid.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1291569     DOI: 10.1093/oxfordjournals.humrep.a137586

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

1.  Does assisted hatching improve implantation rates after in vitro fertilization or intracytoplasmic sperm injection in all patients? A prospective randomized study.

Authors:  S Hellebaut; P De Sutter; D Dozortsev; A Onghena; C Qian; M Dhont
Journal:  J Assist Reprod Genet       Date:  1996-01       Impact factor: 3.412

2.  Transport intracytoplasmic sperm injection (ICSI): a cost-effective alternative.

Authors:  P De Sutter; D Dozortsev; A Verhoeff; T Coetsier; C A Jansen; H C Van Os; M Dhont
Journal:  J Assist Reprod Genet       Date:  1996-03       Impact factor: 3.412

3.  Effects of Anesthetic Agent Propofol on Postoperative Sex Hormone Levels.

Authors:  H Kim; S-Y Ku; H C Kim; C S Suh; S H Kim; Y M Choi
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-04       Impact factor: 2.915

4.  Randomized double-blind clinical trial comparing two anesthetic techniques for ultrasound-guided transvaginal follicular puncture.

Authors:  Gilvandro Lins de Oliveira; Fernando Cesar Serralheiro; Fernando Luiz Affonso Fonseca; Onésimo Duarte Ribeiro; Fernando Adami; Denise Maria Christofolini; Bianca Bianco; Caio Parente Barbosa
Journal:  Einstein (Sao Paulo)       Date:  2016 Jul-Sep

5.  Comparison of chemical pregnancy rates according to the anesthetic method during ultrasound-guided transvaginal oocyte retrieval for in vitro fertilization: a retrospective study.

Authors:  Hyun Joo Heo; Yu Yil Kim; Ji Hye Lee; Han Gyeol Lee; Seung Min Baek; Ki Man Kim
Journal:  Anesth Pain Med (Seoul)       Date:  2020-01-31

6.  The effect of Propofol versus Dexmedetomidine as anesthetic agents for oocyte pick-up on in vitro fertilization (IVF) outcomes.

Authors:  Özcan Budak; Mehmet Sühha Bostancı; AyçaTaş Tuna; Veysel Toprak; Hüseyin Çakiroğlu; Koray Gök
Journal:  Sci Rep       Date:  2021-12-14       Impact factor: 4.379

7.  Comparison of Two Different Sedation Protocols during Transvaginal Oocyte Retrieval: Effects on Propofol Consumption and IVF Outcome: A Prospective Cohort Study.

Authors:  Paraskevi Matsota; Tatiana Sidiropoulou; Tereza Vrantza; Maria Boutsikou; Elena Midvighi; Charalampos Siristatidis
Journal:  J Clin Med       Date:  2021-03-01       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.